- Record: found
- Abstract: not found
- Article: not found
First-line crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase Ⅲ study (PROFILE 1014)
Tony Mok, DW Kim, YL Wu, T Mok, YL WU, T. Kim, Y. Wu, BJ Solomon, K Nakagawa, T Mekhail
2014
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.